This company has been marked as potentially delisted and may not be actively trading. NASDAQ:OTIC Otonomy (OTIC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Otonomy Stock (NASDAQ:OTIC) 30 days 90 days 365 days Advanced Chart Get Otonomy alerts:Sign Up Key Stats Today's Range$0.0085▼$0.008550-Day Range$0.01▼$0.1252-Week Range$0.01▼$2.54VolumeN/AAverage Volume937,525 shsMarket Capitalization$582.48 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA. Read More Receive OTIC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Otonomy and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OTIC Stock News HeadlinesOtonomy, Inc. (OTIC) Stock Historical Prices & Data - Yahoo FinanceJanuary 23, 2023 | finance.yahoo.comOtonomy, Inc.: Otonomy Provides Corporate UpdateDecember 20, 2022 | finanznachrichten.deBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. August 29 at 2:00 AM | Crypto 101 Media (Ad)Otonomy Provides Corporate UpdateDecember 19, 2022 | finance.yahoo.com5 Investors Betting Big on Otonomy (OTIC) StockNovember 30, 2022 | investorplace.comWhy Is Otonomy (OTIC) Stock Up 97% Today?November 29, 2022 | investorplace.comOtonomy Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 10, 2022 | finance.yahoo.comOTIC.OQ - Otonomy Inc | Stock Price & Latest News | ReutersNovember 6, 2022 | reuters.comSee More Headlines OTIC Stock Analysis - Frequently Asked Questions How were Otonomy's earnings last quarter? Otonomy, Inc. (NASDAQ:OTIC) released its quarterly earnings data on Wednesday, November, 10th. The biopharmaceutical company reported ($0.19) EPS for the quarter, meeting the consensus estimate of ($0.19). What other stocks do shareholders of Otonomy own? Based on aggregate information from My MarketBeat watchlists, some other companies that Otonomy investors own include Trevena (TRVN), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), SCYNEXIS (SCYX), Fortress Biotech (FBIO) and OPKO Health (OPK). Company Calendar Last Earnings11/10/2021Today8/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:OTIC CIK1493566 Webwww.otonomy.com Phone(619) 323-2200Fax619-291-9190Employees51Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$51.18 million Net MarginsN/A Pretax MarginN/A Return on Equity-137.86% Return on Assets-68.50% Debt Debt-to-Equity RatioN/A Current Ratio1.74 Quick Ratio1.74 Sales & Book Value Annual Sales$130 thousand Price / Sales4.48 Cash FlowN/A Price / Cash FlowN/A Book Value$0.97 per share Price / Book0.01Miscellaneous Outstanding Shares68,527,000Free Float67,780,000Market Cap$582.48 thousand OptionableOptionable Beta1.54 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:OTIC) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Otonomy, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Otonomy With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access